Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 73 clinical trials
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X)

This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.

  • 16 views
  • 04 Oct, 2022
  • 5 locations
Infliximab for Treatment of Ipilimumab Colitis

This research study is evaluating the effectiveness and safety of infliximab therapy compared with steroids in the treatment of ipilimumab-induced colitis in patients with III/IV melanoma.

combinations
diarrhea
pd-l1
prednisolone
metastasis
  • 10 views
  • 06 Nov, 2021
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the cancer and prevent recurrence after surgery. Treatment given before surgery is called neoadjuvant therapy. The purpose of …

nivolumab
stage iii melanoma
ipilimumab
BRAF
measurable disease
  • 0 views
  • 11 Jul, 2022
  • 1 location
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

The primary objective of this single arm phase 2 trial is to assess the response rate [complete response (CR) + partial response (PR)] of combined nivolumab and HD IL-2 in subjects with metastatic melanoma and renal cell carcinoma. Response will be performed after each course of nivolumab and IL-2 using …

platelet count
direct bilirubin
interleukin 2
renal function
measurable disease
  • 55 views
  • 10 Feb, 2022
  • 1 location
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the time of resection.

serum pregnancy test
mucosal melanoma
direct bilirubin
absolute neutrophil count
metastasis
  • 0 views
  • 09 Apr, 2022
  • 2 locations
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma MSI-H dMMR or NSCLC

A Phase Ib trial to evaluate the safety and efficacy of Fecal Microbial Transplantation (FMT) in combination with Nivolumab in subjects with metastatic or inoperable melanoma, microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR) cancer, or Non-Small Cell Lung Cancer (NSCLC)

  • 0 views
  • 23 Aug, 2021
  • 1 location
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

high-risk resectable melanoma (stage III B / C / D and oligometastatic stage IV).

BRAF
vemurafenib
cobimetinib
measurable disease
braf v600e mutation
  • 29 views
  • 04 May, 2022
  • 3 locations
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma

Modulating the gut microbiome to improve response to immune-checkpoint inhibitors is an active area of study. Prebiotic substances (compounds which positively shift the gut microbiome) are a reliable and safe method of gut microbiome modulation. Data suggest that the berry Camu Camu (CC), also known as Myrciaria dubia has prebiotic …

  • 0 views
  • 04 Oct, 2022
  • 1 location
Surgery of Melanoma Metastases After Systemic Therapy (SUMMIST)

To evaluate if surgical removal of residual disease adds benefit in stage IV melanoma patients with partial response or stable disease after a minimum 9 months of first-line PD-1 inhibition. Primary endpoint: Disease-free survival (DFS) at 12 months.

melanoma stage
metastatic melanoma
systemic therapy
  • 0 views
  • 17 May, 2022
  • 1 location
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders (MITRIC)

This is a single-arm, single-center, open-label, phase IIa study evaluating the safety, feasibility and efficacy of Faecal Microbiota Transplant (FMT) to cancer patients not responding to ICI therapy, using ICI-responders as donors.

carcinoma
platelet count
serum bilirubin
measurable disease
cancer
  • 0 views
  • 07 Oct, 2022
  • 1 location